title: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group.
abstract: Subsets of activated CD8+ lymphocytes defined by membrane expression of the activation antigens HLA-DR and CD38 were counted by three-color flow cytometry in homosexual men who subsequently became seropositive for human immunodeficiency virus type 1 (HIV). Profound CD8+ cell activation was seen in all subjects at seroconversion and 6 and 12 months later. The HLA-DR+ CD38+ CD8+ cell population, which has potent direct HIV cytotoxic T cell activity, was markedly elevated at seroconversion in all subjects. In some men, these levels remained elevated throughout the first year of infection. During the next 5 years, these men had stable CD4+ cell levels, whereas the others did not. Long-term survivors (seropositive for 9 years, > 800 CD4+ cells/mm3) also had elevated levels of this subset, despite few other activated CD8+ cells. Thus, selective elevation of HLA-DR+ CD38- CD8+ cells was a marker of subsequent stable HIV disease.
authors.affiliation: Department of Medicine, University of California, Los Angeles (UCLA).
authors.forename: J V
authors.initials: JV
authors.lastname: Giorgi
authors.forename: H N
authors.initials: HN
authors.lastname: Ho
authors.forename: K
authors.initials: K
authors.lastname: Hirji
authors.forename: C C
authors.initials: CC
authors.lastname: Chou
authors.forename: L E
authors.initials: LE
authors.lastname: Hultin
authors.forename: S
authors.initials: S
authors.lastname: O'Rourke
authors.forename: L
authors.initials: L
authors.lastname: Park
authors.forename: J B
authors.initials: JB
authors.lastname: Margolick
authors.forename: J
authors.initials: J
authors.lastname: Ferbas
authors.forename: J P
authors.initials: JP
authors.lastname: Phair
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D015703:Antigens, CD / Q000032:analysis; D000943:Antigens, Differentiation / Q000032:analysis; D001727:Bisexuality; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D005434:Flow Cytometry; D005500:Follow-Up Studies; D018023:HIV Seronegativity / Q000276:immunology; D006679:HIV Seropositivity / Q000276:immunology* / Q000401:mortality; D006684:HLA-DR Antigens / Q000276:immunology*; D018451:Homosexuality, Male; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008562:Membrane Glycoproteins; D011237:Predictive Value of Tests; D012016:Reference Values; D016019:Survival Analysis; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D006684:HLA-DR Antigens; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1